128 | Humans |
116 | Influenza |
100 | Human |
84 | Influenza, Human (epidemiology) |
83 | Public health |
76 | France |
70 | Influenza A |
69 | Vaccine |
53 | Vaccination |
51 | Influenza, Human (prevention & control) |
49 | Prevention |
49 | Adult |
48 | H1N1 influenza |
48 | Epidemiology |
47 | Female |
45 | Influenza A virus |
39 | Male |
38 | Middle Aged |
37 | Avian influenza |
34 | Medicine |
34 | Child |
33 | Pandemics |
33 | Animals |
32 | Epidemic |
31 | Infection |
30 | COVID-19 |
29 | Young Adult |
28 | Influenza, Human (virology) |
28 | Immunoprophylaxis |
28 | Adolescent |
27 | Antiviral |
26 | France (epidemiology) |
26 | Aged |
23 | Disease Outbreaks |
22 | Sanitary surveillance |
22 | Influenza A (H1N1) |
21 | Disease Outbreaks (prevention & control) |
20 | Resuscitation |
19 | Microbiology |
19 | Europe |
18 | Influenza A Virus, H1N1 Subtype (immunology) |
18 | Child, Preschool |
18 | 2009 |
17 | Pandemic |
17 | Influenza Vaccines (administration & dosage) |
17 | Infant |
16 | pandemic |
16 | Treatment |
16 | Pregnancy |
16 | Intensive care |
16 | Influenza Vaccines (immunology) |
15 | Surveillance |
14 | Virus |
14 | Seasons |
14 | Influenza, Human (transmission) |
14 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
13 | Influenzavirus |
13 | Influenza, Human (diagnosis) |
13 | Influenza virus |
13 | Influenza A Virus, H1N1 Subtype |
13 | Aged, 80 and over |
12 | Vaccination (statistics & numerical data) |
12 | Swine |
12 | Influenza, Human (immunology) |
12 | Antiviral Agents (therapeutic use) |
11 | Toxicity |
11 | Review |
11 | Respiratory distress |
11 | Influenza, Human (mortality) |
11 | Influenza Vaccines |
11 | HIV |
10 | Risk factor |
10 | Risk Factors |
10 | Prospective Studies |
10 | Pediatrics |
10 | Influenza, Human (drug therapy) |
10 | Influenza A Virus, H1N1 Subtype (genetics) |
10 | Infant, Newborn |
10 | Immunological adjuvant |
10 | Hospital |
10 | H1N1 |
10 | French |
10 | Covid-19 |
10 | Acute |
9 | Viral disease |
9 | Respiratory disease |
9 | Pneumonia |
9 | Oseltamivir |
9 | Obesity |
9 | Intensive care unit |
9 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
9 | Incidence |
9 | Immune response |
9 | Global Health |
9 | Epidemics |
9 | Diagnosis |
9 | China |
9 | Army |
9 | AIDS |
8 | covid-19 |
8 | Vaccination coverage |
8 | Travel |
8 | Immunogenicity |
8 | Immunization |
8 | Coronavirus |
8 | Chemotherapy |
7 | virus |
7 | epidemic |
7 | Zoonosis |
7 | World |
7 | Tropical medicine |
7 | Seasonal variation |
7 | SARS-CoV-2 |
7 | Risk |
7 | Risk management |
7 | Public Health |
7 | Pandemics (prevention & control) |
7 | Mortality |
7 | Military environment |
7 | Influenzavirus A(H5N1) |
7 | Influenzavirus A(H1N1) |
7 | Health Policy |
7 | HIV-1 |
7 | Emerging disease |
7 | Clinical management |
6 | public health |
6 | mobility |
6 | health |
6 | geography |
6 | World Health Organization |
6 | Transmission |
6 | Time Factors |
6 | Recommendation |
6 | Population Surveillance |
6 | Mouse |
6 | Influenza A Virus, H5N1 Subtype (immunology) |
6 | Influenza A Virus, H1N1 Subtype (physiology) |
6 | Genetic reassortment |
6 | Computer Simulation |
6 | Anesthesia |
5 | pollution |
5 | coronavirus |
5 | Wuhan |
5 | Veterinary |
5 | Vaccines |
5 | United States |
5 | Severity of Illness Index |
5 | Severe acute respiratory syndrome |
5 | Respiratory tract |
5 | Pneumology |
5 | Physician |
5 | Models, Statistical |
5 | Modeling |
5 | Mexico |
5 | Italy |
5 | Influenza, Human (complications) |
5 | Humoral immunity |
5 | Hospitalization |
5 | Hemagglutinin |
5 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
5 | Hemagglutination Inhibition Tests |
5 | Flulike syndrome |
5 | Exo-α-sialidase |
5 | Evolution |
5 | Europe (epidemiology) |
5 | Efficiency |
5 | Detection |
5 | Decision Making |
5 | Cross-Sectional Studies |
5 | Comparative study |
5 | Cohort study |
5 | Cohort Studies |
5 | Cell Line |
5 | Case history |
5 | Bioterrorism |
5 | Avian influenzavirus |
5 | Attitude of Health Personnel |
5 | Asia |
5 | Arbovirus |
5 | Age Distribution |
5 | Humans |
4 | vulnerability |
4 | vaccination |
4 | urban economy |
4 | transport |
4 | territories |
4 | telework |
4 | obesity |
4 | local development |
4 | internal migration |
4 | influenza |
4 | economy |
4 | economic geography |
4 | cities |
4 | Zoonoses (virology) |
4 | Zika virus |
4 | Virology |
4 | Treatment Outcome |
4 | Serology |
4 | Sensitivity and Specificity |
4 | Reverse transcription polymerase chain reaction |
4 | Reunion island |
4 | Retrospective Studies |
4 | Prognosis |
4 | Pig |
4 | Patient |
4 | Pathogenicity |
4 | Oseltamivir (therapeutic use) |
4 | Narcolepsy |
4 | Mutation |
4 | Models, Theoretical |
4 | Models, Biological |
4 | Mice |
4 | Malignant tumor |
4 | Influenzavirus A |
4 | Influenza, Human (blood) |
4 | Influenza viruses |
4 | Influenza in Birds (epidemiology) |
4 | Influenza Vaccines (adverse effects) |
4 | Influenza A virus (classification) |
4 | Immunology |
4 | History, 20th Century |
4 | Health staff |
4 | Health policy |
4 | Health care staff |
4 | Hazard |
4 | Emergence |
4 | Dogs |
4 | Disease Outbreaks (statistics & numerical data) |
4 | Complication |
4 | Birds |
4 | Antibiotic |
4 | Aids |
4 | Age |
4 | Age Factors |
4 | Africa |
4 | Adaptation |
3 | value chains |
3 | telecommunications |
3 | surveillance |
3 | risk |
3 | repatriation |
3 | pandémie |
3 | lockdown |
3 | international migration |
3 | influenza A virus |
3 | floating population |
3 | epidemiology |
3 | containment |
3 | confinement |
3 | circular economy |
3 | Zoonoses (epidemiology) |
3 | Yersinia pestis |
3 | Virulence |
3 | Vibrio cholerae |
3 | Use |
3 | United States (epidemiology) |
3 | Taiwan |
3 | Survey |
3 | Subtype |
3 | Socioeconomic Factors |
3 | Simulation |
3 | Severe |
3 | Sentinel Surveillance |
3 | Sanitary program |
3 | Safety |
3 | Risk perception |
3 | Rhinovirus (isolation & purification) |
3 | Reverse Transcriptase Polymerase Chain Reaction |
3 | Reunion (epidemiology) |
3 | Result |
3 | Respiratory Distress Syndrome, Adult (therapy) |
3 | Resistance |
3 | Recipient |
3 | Reassortant Viruses (pathogenicity) |
3 | Reassortant Viruses (genetics) |
3 | Real time |
3 | Quarantine |
3 | Public health organization |
3 | Prospective |
3 | Poultry |
3 | Polymerase chain reaction |
3 | Phylogeography |
3 | Pathogenic |
3 | Pathogenesis |
3 | Pandemic influenza |
3 | Pandemic Risk |
3 | Oxygenation |
3 | Oxygen |
3 | Obstetrics |
3 | Neutralization Tests |
3 | Neuraminidase inhibitor |
3 | Models |
3 | Military |
3 | Military Personnel |
3 | Microorganism |
3 | Mathematical model |
3 | Management |
3 | Knowledge |
3 | Interviews as Topic |
3 | Influenza, Human (therapy) |
3 | Influenza, Human (history) |
3 | Influenza in Birds (transmission) |
3 | Influenza Vaccines (therapeutic use) |
3 | Influenza A virus (physiology) |
3 | Influenza A virus (pathogenicity) |
3 | Influenza A virus (genetics) |
3 | Influenza A Virus |
3 | Influenza A Virus, H5N1 Subtype |
3 | Influenza A Virus, H5N1 Subtype (genetics) |
3 | Influenza A Virus, H1N1 Subtype (growth & development) |
3 | Infectious diseases |
3 | Indian Ocean |
3 | In vitro |
3 | Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use) |
3 | Human immunodeficiency virus |
3 | History |
3 | Hemorrhagic fever |
3 | Hemagglutinin Glycoproteins, Influenza Virus (metabolism) |
3 | Hemagglutinin Glycoproteins, Influenza Virus (immunology) |
3 | Health service |
3 | Health and environment |
3 | Health Knowledge, Attitudes, Practice |
3 | HIV/AIDS |
3 | H5N1 |
3 | H1N1 Subtype |
3 | Gynecology |
3 | Genotype |
3 | Genetic vaccine |
3 | General practitioner |
3 | General practice |
3 | Follow-Up Studies |
3 | Fatal course |
3 | Extracorporeal Membrane Oxygenation (methods) |
3 | Evaluation |
3 | Estimation |
3 | Emergency |
3 | Drug |
3 | Disease |
3 | Disease Outbreaks (history) |
3 | Disease Models, Animal |
3 | Disaster |
3 | Decision aid |
3 | Comorbidity |
3 | Communicable Disease Control (methods) |
3 | Clinical trial |
3 | Clinical biology |
3 | Chemoprophylaxis |
3 | Check |
3 | Cataplexy |
3 | Cameroon |
3 | Calcitonin (blood) |
3 | Bibliographic review |
3 | Bacteriosis |
3 | Aves |
3 | Antibody |
3 | Antibodies |
3 | Animal |
3 | Amino Acid Sequence |
3 | Aedes aegypti |
3 | Pandemics |
2 | vaccine |
2 | outbreak |
2 | origin |
2 | neutralizing antibodies |
2 | membrane fusion |
2 | mathematical modelling |
2 | influenza virus |
2 | inflammation |
2 | immunity |
2 | hepatitis e virus |
2 | global change |
2 | flu |
2 | experimental evolution |
2 | epidemics |
2 | epidemic model |
2 | enseignement à distance |
2 | demography |
2 | crise sanitaire |
2 | covid-19 pandemic |
2 | conditions de logement |
2 | age |
2 | Zoonoses (transmission) |
2 | Zanamivir |
2 | Workforce |
2 | Woman |
2 | Winter |
2 | Virus Diseases |
2 | Virulence Factors (metabolism) |
2 | Virulence Factors (genetics) |
2 | Viral membrane fusion |
2 | Viral load |
2 | Viral hepatitis B |
2 | Vietnam |
2 | Vector |
2 | Vaccines, Attenuated |
2 | Vaccination (economics) |
2 | Typing |
2 | Tuberculosis |
2 | Travel (statistics & numerical data) |
2 | Toxoplasma gondii |
2 | Time to the most recent common ancestor (TMRCA) |
2 | Sustainability |
2 | Surveys and Questionnaires |
2 | Sub-Saharan Africa |
2 | Streptococcus pneumoniae |
2 | Strategy |
2 | Statin derivative |
2 | Spoligotyping |
2 | Spanish flu |
2 | South east Asia |
2 | Solvency II |
2 | Simulation model |
2 | Sequence analysis |
2 | Sequence Analysis, DNA |
2 | Sequence Alignment |
2 | Selection pressure |
2 | Schools (organization & administration) |
2 | School environment |
2 | SIV |
2 | SIR model |
2 | SARS-CoV |
2 | Rimantadine (therapeutic use) |
2 | Rheumatology |
2 | Respiratory system infection |
2 | Respiratory support |
2 | Respiratory Tract Infections (epidemiology) |
2 | Respiratory Distress Syndrome, Adult (mortality) |
2 | Respiration, Artificial (methods) |
2 | Reservoir |
2 | Research and development |
2 | Reassortant Viruses (physiology) |
2 | Rapid technique |
2 | RNA Replicase (metabolism) |
2 | RNA Replicase (genetics) |
2 | Quantitative analysis |
2 | Pulmonary Disease, Chronic Obstructive (epidemiology) |
2 | Public Opinion |
2 | Public Health (methods) |
2 | Psycholinguistics |
2 | Protein Precursors (blood) |
2 | Protective mask |
2 | Protection Insurance |
2 | Probability |
2 | Primary care |
2 | Preparation |
2 | Pregnancy Outcome |
2 | Pregnancy Complications, Infectious (virology) |
2 | Pregnancy Complications, Infectious (prevention & control) |
2 | Pregnancy Complications, Infectious (epidemiology) |
2 | Predictive factor |
2 | Prediction |
2 | Practice Guidelines as Topic |
2 | Poverty |
2 | Population surveillance |
2 | Polymerase Chain Reaction |
2 | Policy Making |
2 | Pneumopathy |
2 | Pneumonia (virology) |
2 | Pneumococcal infection |
2 | Planning |
2 | Plague |
2 | Picornaviridae Infections (epidemiology) |
2 | Phylogenetic analysis |
2 | Phylogenetic analyses |
2 | Phase III trial |
2 | Pharmacovigilance |
2 | Peptides (immunology) |
2 | Peptides (chemistry) |
2 | Patient Acceptance of Health Care |
2 | Pandemics (history) |
2 | Pandemic influenza A/H1N1 |
2 | Overlapping genes |
2 | Outbreak |
2 | Orthomyxoviridae Infections (virology) |
2 | Orthomyxoviridae Infections (immunology) |
2 | Orthomyxoviridae (pathogenicity) |
2 | Orthomyxoviridae (immunology) |
2 | Organization |
2 | On line |
2 | Occupational medicine |
2 | Occupational exposure |
2 | Neutralizing antibodies |
2 | Network |
2 | Neonatal |
2 | Mutation (genetics) |
2 | Multiplex polymerase chain reaction |
2 | Mortalité |
2 | Mortality Risk |
2 | Molecular epidemiology |
2 | Molecular Sequence Data |
2 | Models, Immunological |
2 | Modelling |
2 | Model |
2 | Mobility |
2 | Mice, Inbred BALB C |
2 | Mexico (epidemiology) |
2 | Method |
2 | Metapopulation |
2 | Mechanical ventilation |